Research progress on the role of exosome in rejection after lung transplantation
10.3969/j.issn.1674-7445.2022.04.018
- VernacularTitle:外泌体在肺移植排斥反应中的作用研究进展
- Author:
Guanyu JIANG
1
;
Siyuan CHEN
;
Yongrui XU
;
Mingfeng ZHENG
;
Wenjun MAO
Author Information
1. Department of Thoracic Surgery, the Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi 214023, China
- Publication Type:Research Article
- Keywords:
Lung transplantation;
Exosome;
Chronic lung allograft dysfunction (CLAD);
Acute cellular rejection (ACR);
Restrictive allograft syndrome (RAS);
Bronchiolitis obliterans syndrome (BOS);
Major histocompatibility complex (MHC);
Donor specific antibody (DSA)
- From:
Organ Transplantation
2022;13(4):530-
- CountryChina
- Language:Chinese
-
Abstract:
Rejection after lung transplantation, including acute rejection (AR) and chronic rejection manifested with chronic lung allograft dysfunction (CLAD), is the main factor affecting the long-term survival of allografts. Exosome, a type of extracellular nanovesicle for intercellular communication among eukaryotic cells, could carry complex biological information and participate in various physiological and pathological processes. Exosome has become a critical immune medium in rejection, regulates the incidence and development of rejection through multiple pathways, and also plays a key role in the monitoring and management of rejection. In this article, the type of rejection after lung transplantation, the mechanism underlying the role of exosome in regulating rejection, exosome acting as biomarkers and the application in rejection treatment were reviewed, aiming to provide a novel direction for comprehensive diagnosis and treatment of rejection following lung transplantation.
